Moderna’s land grab
Can Moderna make the case for mRNA after its record IPO?
A blockbuster IPO by Moderna Inc. (NASDAQ:MRNA) gives the company the opportunity to make the case for mRNA.
With more money, and a broader and more advanced pipeline than other players in the mRNA space, Moderna could establish itself as a leader across several treatment paradigms. But it needs to prove itself with data.
Late Thursday, the company set the record for the largest NASDAQ IPO for a biotech, raising $604.3 million in an upsized offering